

PO BOX 220, MONCTON (NB) E1C 8L3 TEL.: 1-800-667-4511 FAX: 1-844-661-2640 PO BOX 3300, STATION B, MONTREAL (QC) H3B 4Y5 TEL.: 1-888-873-9200 FAX: 1-514-286-8480

## CANNABIS FOR MEDICAL PURPOSES PRIOR AUTHORIZATION REQUEST

## i

## PROCEDURES FOR PRIOR AUTHORIZATION

Completed forms can be faxed in confidence to 1-514-286-8480 for residents of Quebec and 1-844-661-2640 for residents of all other provinces

Upon receipt, this request will be confidentially reviewed according to payment criteria developed by Blue Cross in consultation with independent health care consultants. In some cases, additional clinical and/or diagnostic information may be required in order to process your claim.

- Prior Authorization is a pre-approval process to determine if certain products will be reimbursed under a member's benefit plan.
- Please complete entire form. Incomplete forms cannot be processed.
- Requests for coverage will only be considered for members of benefit plans where Cannabis for Medical Purposes has been included as an eligible Extended Health Care benefit.
- Requests for coverage will only be considered for fresh/dried cannabis flower or cannabis oil, and only when other second / third line treatments have been tried and failed.
- Prior Authorization may be limited to a specified time period and/or annual dollar maximum.
   Cannabis for Medical Purposes must be obtained directly through a Health Canada approved Licensed Producer.
- In cases where a request for Prior Authorization is declined, Blue Cross is denying payment for a product and is not challenging the medical opinion of the physician nor rendering a medical opinion.
- Any costs associated with the completion of this form or obtainment of additional medical information are the responsibility of the member.
- Renewal of the Prior Authorization will be considered by Blue Cross upon request from the patient/member. The renewal request should include information from the physician supporting continued use of Cannabis for Medical Purposes.
- Prior Authorization coverage is contingent on your continued status as a Blue Cross cardholder or beneficiary.





PO BOX 220, MONCTON (NB) E1C 8L3 TEL.: 1-800-667-4511 FAX: 1-844-661-2640 PO BOX 3300, STATION B, MONTREAL (QC) H3B 4Y5 TEL.: 1-888-873-9200 FAX: 1-514-286-8480

## CANNABIS FOR MEDICAL PURPOSES PRIOR AUTHORIZATION REQUEST

1 POLICY INFORMATION			
Plan Member Name			
Plan Member Name:Address:			Postal Code:
Telephone Number:			
2 PATIENT INFORMATION			
Part A			
Is Patient also the Plan Member?	es 🗌 No 🔲 Current address sa	me as above (if not, please com	plete applicable fields below)
Patient Name (if not plan member):			
Addrage:	City:	Province:	Postal Code:
Telephone Number:	ID Number:	Date of Birth:	
Do you have valid Medicare coverage in	current province of residence?	Yes 🗌 No	(mm/dd/yyyy)
Have you already purchased Cannabis f	or Medical Purposes?	No	
If yes, please attach your paid-in-full receive the date of the oldest receipt.	ceipt with this request form. If you ha	ve already submitted your receip	ot to Blue Cross, please indicate
Date :			
Part B – Coordination of Benefits			
Do you or any dependants have coverage if Yes, complete the following:	ge for Cannabis for Medical Purpose	s under any other plan or progra	m?
Policy Number:	Carrier: tach Explanation of Benefits from prior ca	union with a complete forms	
If the patient is a dependent, provide the	tach Explanation of Benefits from prior ca	ler for the other carrier:	
ii iio patieni is a dependent, provide tre	birti day and month of the cardiole	(dd/mn	n)
Part C – Authorization			
I hereby authorize any health care p which relates to claims submitted by			out myself and my dependents
I understand that the personal informatic Blue Cross and/or Blue Cross Life Insurate the group policy of which I am an eligibusiness. Depending on the type of confidence third parties include other Blue Confidence of the benefits outlined in the policy of which	ance Company of Canada, may be or gible member, to recommend suita everage I carry, limited personal inforces cross organizations, health care professional under which I am a participal	collected, used, or disclosed to a ble products and services to r cormation may be collected from fessionals or institutions, life and	dminister the terms of my policy or me, and to manage Blue Cross's a and/or released to a third party. It health insurers, government and
I understand that my personal information however, in some instances doing so my personal information is needed and I	nay prevent Blue Cross from providi	ng me with the requested cover	age or benefits. I understand why
I authorize Blue Cross to collect, use and	d disclose my personal information a	s described above.	
Signature of Patient:		Date:	
_			(mm/dd/yyyy)
A photocopy of this authorization shall be as privacy policies at Blue Cross, visit			



3 CANNABIS FOR MEDICAL PURPOSES	SINFORMATION				
	of patient: Date of Birth :				
Policy Number:	ID Number:				
For Initial Request, please cor	nplete Sections 3A and	<u>l 3B. For Renewals, pleas</u>	se complete Sections 3A and 3C		
3A Prior Authorization Information – Man	datory				
Product Name	Strength	Dosage	Diagnosis		
CANNABIS FOR MEDICAL PURPOSES	% THC % CBD	grams/day			
Method of administration:					
This request pertains to which of the following	☐ Canna	/ dried cannabis flower abis oil / oil capsules Specify:			
Mandatory information  Patient has provided a copy of the Medic *Access to Cannabis for Medical Purposes Re	y requests for the medic	ical conditions listed belo			
Patient has registered with a Licensed F *** Patient must be registered with a Health			roof must be submitted with first claim ***		
Please answer all the questions pertaining to	the medical condition for	r which this treatment is pre	escribed		
Refractory Neuropathic Pain					
Indicate if there has been a reasonable the arrangement of the tricyclic antidepressants, gabapentinoid	•	, ,	ng:		
Indicate if there has been a reasonable the	•	, ,	ng:  Response to Treatment or Contraindication		
Indicate if there has been a reasonable the arrangement of the tricyclic antidepressants, gabapentinois	ids, SNRIs, prescribed m	nedical cannabinoids			
Indicate if there has been a reasonable the arrangement of the tricyclic antidepressants, gabapentinois	ids, SNRIs, prescribed m	nedical cannabinoids			

				Data of Pirth :
Name of patient: Date of Birth Policy Number: ID Number:				Date of Birth :
B Initial Request (co	 ont'd)			
	•			
2. Refractory pain i	n palliative cancer patie	nt		
Indicate if there has	been a reasonable therap	peutic trial with at I	east two (2) of the following	:
- Opioids, antidepre	essants, anticonvulsants, o	dexamethasone, ti	zanidine, prescribed medical	cannabinoids
Category	Product Name	Dosage	Duration of Treatment	Response to Treatment or Contraindication
Category	1 Toddet Name	Dosage	Duration of Treatment	response to Treatment of Contramulation
	_			
3. Chemotherapy-ir	nduced nausea and vom	iting (CINV)		
Expected duration of	of chemotherapy:			
	ed adequately despite pre	ventative therapy	including serotonin receptor	antagonist and at least one (1) of the
following:				
- Dexamethasone,	NK1 antagonist, dopamine	e antagonist, preso	cribed medical cannabinoids	
Category	Product Name	Dosage	Duration of Treatment	Response to Treatment or Contraindication
4. Spasticity in Mul	tiple Sclerosis (MS) or S	pinal Cord Injury	(SCI)	
	tiple Sclerosis (MS) or S			
Indicate if there has	s been a reasonable therap	peutic trial with the	following:	prescribed medical cannabinoids
Indicate if there has - Baclofen, gabape	s been a reasonable therap	peutic trial with the	following: odiazepines, botulinum toxin	·
Indicate if there has	s been a reasonable therap	peutic trial with the	following:	prescribed medical cannabinoids  Response to Treatment or Contraindication
Indicate if there has - Baclofen, gabape	s been a reasonable therap	peutic trial with the	following: odiazepines, botulinum toxin	·
Indicate if there has - Baclofen, gabape	s been a reasonable therap	peutic trial with the	following: odiazepines, botulinum toxin	·
Indicate if there has - Baclofen, gabape	s been a reasonable therap	peutic trial with the	following: odiazepines, botulinum toxin	·
Indicate if there has - Baclofen, gabape	s been a reasonable therap	peutic trial with the	following: odiazepines, botulinum toxin	·

3 CANNABIS FOR MEDICAL PURPOSES INFORMATION	
Name of patient:	Date of Birth :
Policy Number:	ID Number:
3B Initial Request (cont'd)	
5. Please indicate any additional information pertaining to thi	is request:
3C Renewal Request	
Please provide information on the evolution of the disease to eva	aluate the response to treatment
Date of initial evaluation (pre-treatment):(mm/dd/yyyy)	Date of most recent evaluation: (mm/dd/yyyy)
1. Specify the condition for which the continuation of treatme	ont is requested:
	ant is requested.
Refractory neuropathic pain	
<ul><li>☐ Refractory pain in palliative cancer patient</li><li>☐ Chemotherapy-induced nausea and vomiting (CINV)</li></ul>	
☐ Spasticity in Multiple Sclerosis (MS) or Spinal Cord Injury (SC	:D
	<b>'</b>
Provide all the data showing the patient has experienced a position	ve therapeutic response to treatment:
2. Please indicate any additional information pertaining to thi	is request
4 PHYSICIAN STATEMENT	
Physician Name:	Specialty:
Telephone Number:	
Physician Signature:	Date:(mm/dd/yyyy)